Physician

Burhan Haleem, D.O.

According to 2025 Medicare claims, Burhan Haleem, D.O. (NPI: 1467740811) practices interventional pain management (ipm) in the Camden, NJ market, with the plurality of this provider's patient population coming from Gloucester, NJ. This provider's primary affiliated billing organization is PREMIER BRAIN AND SPINE, LLC (NPI: 1922771377; TIN: 871737086) and primary practice location at 08080-9229.

Haleem's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 529 traditional Medicare patients, billed 4,933 HCPCS/CPT codes, and received $334,123 in Medicare payments. The top billing code was G0480 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 3,132 prescription claims across 472 beneficiaries totaling $247,597 in drug costs, led by Relistor (Methylnaltrexone Bromide). 2017 DME data shows 41 claims. Open Payments data shows 82 records totaling $1,233. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $53,625 and ending at $334,123. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $1,526 and ending at $247,597. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	239	562	$53,625
2017	556	3,096	$310,194
2018	1,062	5,487	$434,876
2019	820	5,027	$350,498
2020	631	4,797	$270,200
2021	718	5,347	$374,039
2022	540	3,773	$251,516
2023	507	3,758	$253,492
2024	529	4,933	$334,123

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	30	51	$1,526
2016	256	505	$72,588
2017	558	2,958	$471,376
2018	689	3,162	$504,584
2019	648	2,600	$455,905
2020	539	3,411	$383,332
2021	444	1,795	$235,212
2022	438	2,817	$373,024
2023	434	2,711	$373,467
2024	472	3,132	$247,597

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	41	41	$30,919
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	300	567	$110
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	272	517	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	432	1,322	$69
80307	Testing for presence of drug, by chemistry analyzers	338	615	$60
99484	Care management services for behavioral health conditions, 20 minutes or more clinical staff time directed by health care professional	257	343	$45

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Relistor	Methylnaltrexone Bromide	26	780	$60,706
Ztlido	Lidocaine	48	1,605	$32,891
Belbuca	Buprenorphine Hcl	34	1,020	$22,457
Oxycontin	Oxycodone Hcl	49	1,440	$17,888
Diclofenac Sodium	Diclofenac Sodium	189	6,320	$13,154

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	82	$1,233	Collegium Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Burhan Haleem, D.O.?

Tedicare shows public-source Medicare data for Burhan Haleem, D.O. (NPI 1467740811), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Burhan Haleem, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Burhan Haleem, D.O.?

Burhan Haleem, D.O. is linked to PREMIER BRAIN AND SPINE, LLC (billing NPI 1922771377) in the available physician profile data.

Does Burhan Haleem, D.O. have Open Payments data?

Burhan Haleem, D.O. has 82 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.